Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373226 | 1.00 | BCHE (0.81) | BCHEACHE | |
| SCHEMBL3373894 | 1.00 | BCHE (0.81) | BCHEACHE | |
| SCHEMBL3372518 | 0.99 | BCHE (0.79) | BCHEACHE | |
| SCHEMBL5486994 | 0.93 | BCHE (0.71) | BCHEACHE | |
| SCHEMBL22470350 | 0.91 | ACHE (0.79) | BCHEACHE | |
| SCHEMBL16667274 | 0.88 | ACHE (0.81) | BCHEACHE | |
| SCHEMBL16667433 | 0.88 | ACHE (0.81) | BCHEACHE | |
| SCHEMBL14125685 | 0.88 | ACHE (0.81) | BCHEACHE | |
| SCHEMBL8518647 | 0.87 | ACHE (0.89) | BCHEACHE | |
| SCHEMBL8512770 | 0.87 | ACHE (0.89) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646622-B1 | TACRINE DERIVATIVES AS INHIBITORS OF ACETYLCHOLINESTERASE | NOSCIRA SA (ES) | 2010-11-03 | — | — | EP | claimed |
| EP-1646622-A1 | TACRINE DERIVATIVES AS INHIBITORS OF ACETYLCHOLINESTERASE | Neuropharma S.A.U. (ES) | 2006-04-19 | — | — | EP | claimed |
| US-20050148621-A1 | Acetylcholinesterase dual inhibitors | NOSCIRA, S.A. (ES) | 2005-07-07 | — | — | US | claimed |
| WO-2005005413-A1 | TACRINE DERIVATIVES AS INHIBITORS OF ACETYLCHOLINESTERASE | NEUROPHARMA S.A. (ES) | 2005-01-20 | — | — | WO | claimed |
| EP-1646622-B1 | TACRINE DERIVATIVES AS INHIBITORS OF ACETYLCHOLINESTERASE | NOSCIRA SA (ES) | 2010-11-03 | — | — | EP | disclosed |
| EP-1646622-A1 | TACRINE DERIVATIVES AS INHIBITORS OF ACETYLCHOLINESTERASE | Neuropharma S.A.U. (ES) | 2006-04-19 | — | — | EP | disclosed |
| US-20050148621-A1 | Acetylcholinesterase dual inhibitors | NOSCIRA, S.A. (ES) | 2005-07-07 | — | — | US | disclosed |
| WO-2005005413-A1 | TACRINE DERIVATIVES AS INHIBITORS OF ACETYLCHOLINESTERASE | NEUROPHARMA S.A. (ES) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148621-A1 | Acetylcholinesterase dual inhibitors | ACHE, BCHE, BACE1 | BCHE 2/4885ACHE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.